A 68-year-old man with diabetes mellitus presents to the emergency department with fever (39.2°C), dysuria, and flank pain for 3 days. He has a history of recurrent urinary tract infections treated with fluoroquinolones and cephalosporins over the past 2 years. Urine culture yields a gram-negative rod. On antibiotic susceptibility testing, the organism is resistant to ceftriaxone and cefotaxime but susceptible to carbapenems and fluoroquinolones. The resistance is not reversed by clavulanic acid. What is the most likely resistance mechanism in this isolate?

Explanation

## Resistance Mechanism Analysis ### Key Clinical Clue: Clavulanic Acid Non-Reversal **Key Point:** The resistance pattern—cephalosporin resistance NOT reversed by clavulanic acid—is pathognomonic for AmpC β-lactamase, not ESBL. ### Differential Interpretation of Susceptibility Pattern | Feature | ESBL | AmpC β-lactamase | |---------|------|------------------| | Cephalosporin resistance | Yes | Yes | | Carbapenem resistance | No (susceptible) | No (susceptible) | | Clavulanic acid reversal | **Yes** | **No** | | Fluoroquinolone activity | Variable | Often retained | | Common organisms | *E. coli*, *Klebsiella* | *Enterobacter*, *Citrobacter*, *Serratia* | | Inducible resistance | No | Yes (inducible in some) | ### Mechanism of AmpC β-Lactamase 1. **Structure**: AmpC is a serine β-lactamase with a different active site from ESBLs 2. **Substrate spectrum**: Hydrolyzes 3rd-generation cephalosporins (ceftriaxone, cefotaxime) AND clavulanic acid itself 3. **Why clavulanic acid fails**: AmpC is not inhibited by clavulanic acid because: - Clavulanic acid is a substrate for AmpC (gets hydrolyzed) - Does not bind stably to the AmpC active site 4. **Carbapenem stability**: Carbapenems are highly resistant to AmpC hydrolysis due to their β-methyl group **High-Yield:** AmpC resistance = cephalosporin resistance + **clavulanic acid-resistant** + carbapenem-susceptible. ### Clinical Pearl **Clinical Pearl:** Recurrent UTI history with prior cephalosporin/fluoroquinolone exposure increases risk of selecting AmpC-producing organisms (especially *Enterobacter* species), which are common nosocomial pathogens. ### Treatment Implications - **DOC**: Carbapenems (meropenem, imipenem) or fluoroquinolones (if susceptible) - **Avoid**: 3rd-generation cephalosporins, even with β-lactamase inhibitors - **Note**: 4th-generation cephalosporins (cefepime) may have variable activity against AmpC [cite:Koneman's Textbook of Diagnostic Microbiology Ch 6]